logo
Tower of London dig unveils possible links to Black Death

Tower of London dig unveils possible links to Black Death

Yahoo17-07-2025
The first major excavation at the Tower of London in 30 years has uncovered what experts believe could be a Black Death burial site, hidden for centuries beneath the chapel where Anne Boleyn is buried.
Archaeologists have found the remains of at least 20 individuals beneath the Chapel of St Peter Ad Vincula, including a collection of burials from the 14th century in what could have been a mass grave.
Wiping out around three million people, out of an estimated six million in England at the time, the Black Death swept the country in the 14th century.
Alfred Hawkins, curator of historic buildings at Historic Royal Palaces (HRP), which manages the Tower of London, described the findings as a 'generational opportunity to enhance our understanding of the evolution of the Chapel of Saint Peter ad Vincula and the buildings which stood before it'.
Some of the remains, from the 12th and 13th centuries were buried in coffins, which HRP says may indicate 'high-status' burials.
Alongside the coffins, a fragment of a burial shroud was found, an exceptionally rare discovery as textiles often do not survive in such conditions.
Two further burial sites have also been discovered that contain 13th century charcoal pots, similar artefacts have only been found once before at an archaeological site elsewhere in England.
The dig also unearthed signs of three successive chapels constructed on the site, with evidence of fire damage, medieval stonework, and rare artefacts dating back to the reign of Henry I in the 12th century.
Carried out ahead of the installation of a new lift to improve accessibility to the chapel, the excavation was approved and monitored by Historic England.
Dr Katie Faillace, an archaeologist based at Cardiff University's School of History, said: 'The new excavations provide the opportunity to transform our understanding of the Tower's community.
'Our work uses a biomolecular technique known as isotope analysis, which tells us about health, diet and mobility in the past, all from a tiny fragment of a tooth.
'This cutting-edge method has unparalleled potential for reconstructing the experiences of the people who lived and died at the Tower, allowing us to build a rich picture of individuals' lives.'
The dig is the first major one of its kind on this specific part of the Tower, and enables a redrawing of the map of the medieval fortress which attracts almost three million visitors a year.
Dr Jane Sidell, principal inspector of ancient monuments at Historic England, welcomed the findings.
She said: 'Together we've struck a balance between creating lift access to a fascinating part of the Tower of London, with the complexity of carefully managing a hugely significant and archaeologically rich site.'
She added: 'We're already gaining insight into the residents of the Tower in a way we have never been able to do before.
'But this is just the tip of the iceberg – there is so much more to learn through further analysis about the people as well as the buildings of one of England's most evocative historic monuments.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

4,000-year-old handprint found on ancient Egyptian tomb
4,000-year-old handprint found on ancient Egyptian tomb

CNN

time2 hours ago

  • CNN

4,000-year-old handprint found on ancient Egyptian tomb

FacebookTweetLink A 4,000-year-old handprint has been discovered on a clay model used for offerings in an Ancient Egyptian tomb. Researchers from Cambridge University's Fitzwilliam Museum, in the United Kingdom, stumbled upon the imprint while preparing for an exhibition, which is set to open this fall. It was found on the base of a 'soul house,' a building-shaped clay model typically found in burials and said to have provided a place for the soul to live, according to a press release from the museum. The model has an open space at the front where food offerings, like bread, lettuce or an ox's head, could be placed. Dating back to about 2055–1650 BCE, the soul house underwent extensive examinations that revealed how it was made four millennia ago. It showed that the unnamed potter would have first created a framework of wooden sticks for the two-story building, which was then coated with clay. The firing process would have burnt the wood away. The handprint was found underneath the soul house and was most likely formed when the potter moved the model while the clay was still damp and before it was fired in a kiln. 'We've spotted traces of fingerprints left in wet varnish or on a coffin in the decoration, but it is rare and exciting to find a complete handprint underneath this soul house,' said Helen Strudwick, senior Egyptologist at the museum and curator of the exhibition. 'This was left by the maker who touched it before the clay dried,' she said in the release. 'I have never seen such a complete handprint on an Egyptian object before. You can just imagine the person who made this, picking it up to move it out of the workshop to dry before firing.' 'Things like this take you directly to the moment when the object was made and to the person who made it, which is the focus of our exhibition,' Strudwick added. Vast amounts of pottery have survived from the ancient Egyptian period as ceramics were widely used for functional objects and decorative pieces. It was common for pottery containing food and drink to feature in burials. While much is known about ancient Egyptian rulers like Tutankhamun, the stories of those who made some of the many artifacts discovered in their tombs is often overlooked. The ready availability of clay and low value of pottery is likely to have affected social status of potters, according to the museum. The soul house will be on display at the Cambridge museum as part of the 'Made in Ancient Egypt' exhibition, which aims to highlight the stories of artisans like the one who left this handprint behind. It opens on October 3. Discover your world Go beyond the headlines and explore the latest scientific achievements and fascinating discoveries. Sign up for CNN's Wonder Theory science newsletter.

Centauri Therapeutics Receives an Additional $5.1M from CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials
Centauri Therapeutics Receives an Additional $5.1M from CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials

Yahoo

time4 hours ago

  • Yahoo

Centauri Therapeutics Receives an Additional $5.1M from CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials

CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidate Centauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in human clinical study in early 2026 CARB-X's additional funding brings their financial support to date for the Alphamer platform and lead compound non-clinical development to $12.3M ALDERLEY PARK, England, July 29, 2025--(BUSINESS WIRE)--Centauri Therapeutics Limited ('Centauri' or 'the Company'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound. The funds will contribute to the advancement of the lead candidate in Centauri's ABX-01 programme into first in human clinical studies, and this latest funding brings CARB-X's total support from 2019 to date to $12.3M. Centauri announced the selection of its first clinical candidate in the ABX-01 programme in March 20251. The candidate is a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. Based on the Company's proprietary Alphamer® platform, it is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Early efficacy studies have demonstrated the compound's activity against Gram-negative bacteria. "The unwavering scientific and financial support from CARB-X has provided stability to Centauri as a company, expanded understanding of our Alphamer platform, and enabled us to progress the ABX-01 programme from discovery, through early development, and is now providing a smooth and continuous path towards First in Human clinical studies," said Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics. "We are thankful for CARB-X and their continued engagement and confidence, which has allowed us to move a step closer to delivering a much needed therapeutic for serious, drug-resistant Gram-negative infections, even in the most clinically vulnerable patients." Dr. Erin Duffy, Chief of Research and Development, CARB-X, commented: "We have been proud to support Centauri, beginning with answering key questions on the approach and continuing with the drug discovery that has led to the lead asset of ABX-01 and its progression towards building a dossier to support its advancement into first in human clinical trials." CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany's Federal Ministry of Research, Technology and Space (BMFTR). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. Press Release (4th March, 2025): Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections View source version on Contacts Media contact Katie OdgaardEmail: Tel: +44 (0) 7787 502 947 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

LIfT BioSciences announces grant of €12 million from Ireland's Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT's IMAN therapy
LIfT BioSciences announces grant of €12 million from Ireland's Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT's IMAN therapy

Yahoo

time7 hours ago

  • Yahoo

LIfT BioSciences announces grant of €12 million from Ireland's Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT's IMAN therapy

Galway, London, 29 July 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland's Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026. The €12 million grant, the largest grant awarded by the DTIF to date, was awarded to a consortium LIfT formed with the University of Galway, renowned for their expertise in cell therapy development, innovation, and clinical trials and Hooke Bio, pioneers of a novel immuno-analytics platform designed to enhance therapy response rates, as part of the Company's grant application process. The funding will be used to conduct an investigator initiated clinical trial designed to test the feasibility and safety of IMAN therapy administered to patients with metastatic cervical cancer or head and neck cancer who have exhausted all standard treatment options, including checkpoint inhibitors. Alex Blyth, Chief Executive Officer of LIfT Biosciences, said: 'The grant awarded from DTIF is a significant milestone for LIfT as we expand our presence in Ireland and advance toward closing the second round of our Series A financing. By combining LIfT's innovative immunotherapy platform with the University of Galway's deep expertise in oncology, patient care, and advanced manufacturing, and Hooke Bio's analytical expertise, we are enhancing our clinical-stage research and accelerating the path to delivering IMANs to patients. The majority of this grant will support CMC manufacturing and the clinical trial itself, positioning LIfT at the forefront of next-generation cancer immunotherapies.' Commenting on the award, Peter Burke, Minister for Enterprise, Tourism and Employment, said that 'The Government established the Disruptive Technologies Innovation Fund to invest in technologies that demonstrate true innovation and with the potential to address critical national and societal challenges. We want to fund projects that will make a real difference to people's lives. The N-LIfT project has come through a rigorous evaluation process and the level of funding awarded reflects its potential to be a game-changer in cancer therapy. I'm excited to see the impact it will deliver.' The trial will test progressively higher IMAN doses in sequential patient cohorts to determine the biologically active dose. It will then be expanded to additional patients who will be infused with IMANs at the previously determined recommended dose in combination with checkpoint inhibitor therapy. The results of this evaluation will help bring this promising technology to cancer patients faster and enable LIfT to attract additional investment into Ireland for its ongoing clinical and manufacturing programme in Galway. Dr Michael McCarthy, Consultant Medical Oncologist and Principal Investigator at University Hospital Galway added: 'Cancer remains one of the most complex and dynamic diseases. IMANs have the potential to overcome key limitations of current cancer treatments by activating both the innate and adaptive branches of the immune system. This dual stimulation enables a comprehensive anti-tumour response, representing a transformative advancement in cancer therapy. We are pleased to receive this grant in collaboration with LIfT and Hooke Bio, and we look forward to accelerating the clinical development of this groundbreaking immunotherapy.' Professor Sean Hynes, Consultant Histopathologist and Translational Cancer Researcher from the School of Medicine and Lead Academic on the award commented: 'In partnership with LIfT Biosciences and Hooke Bio, we are very excited about the University of Galway and Galway University Hospital being at the forefront of delivering on new oncological cellular therapies by using neutrophils, the body's own first responders, in the fight against cancer and ensuring patients in the West of Ireland have access to such cutting edge treatments.' Mark Lyons, Ph.D., CEO at Hooke Bio added: 'We're very excited to be able to employ our Mera body on a plate platform to support the development of LIfT's immuno-oncology therapeutic. This project highlights the strength of the Irish clinical research eco system and the power of collaboration.' DTIF is a €500 million challenge-based fund established under Project Ireland 2040. It is one of four funds set up under the National Development Plan (NDP) 2018-2027. It is managed by the Department of Enterprise, Trade and Employment and administered by Enterprise Ireland. The DTIF fund is for clients of Enterprise Ireland, Údarás na Gaeltachta, IDA Ireland and research performing organisations in Ireland that are collaborating on industrial research and / or experimental development in highly innovative projects. LIfT, registered as Eolaíocht Bhitheach LIfT Teoranta, has a base in An Spidéal, Co. Galway at (gteic@An Spidéal) and, as an Údarás na Gaeltachta client, has been supported by them to create employment in the Gaeltacht. About LIfT BioSciencesLIfT BioSciences is a UK and Ireland-based biotech pioneering a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by restoring immune competence. Its Immuno-Modulatory Alpha Neutrophils (IMANs) recognise and destroy cancer cells through advanced threat pattern recognition in a non-antigen-specific manner. Clinical studies show that this class of neutrophils can prevent tumour escape—responsible for over 90% of cancer-related deaths—by delivering a durable, total immune response and lasting immunity. LIfT's patented N-LIfT platform is derived from exceptional donor stem cells cultured in a proprietary enhancement media, enabling scalable and potent cell production. The company is also advancing iPSC technology and genetic engineering to create next-generation IMAN therapies with pharma partners to achieve cost-effective, long-term remission for cancer patients and beyond. LIfT is currently completing its 2nd close on its Series A Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store